ESR1 and breast carcinoma: In this study, we provide the first clinical evaluation of the AI-based Stratipath Breast tool for image-based risk profiling where we compare it with an established multigene assay for risk stratification in a real-world breast cancer case series of clinically intermediate-risk ER+/HER2- tumors.